AXSM vs PSNL: fair value comparison
Axsome Therapeutics, Inc. and Personalis, Inc. · Updated 2026-10-19
AXSM's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. PSNL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PSNL currently ranks higher by quality score.
| AXSM | PSNL | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $157.14 | $15.65 |
| 12-month range | $127.06–$255.17 | $5.04–$18.38 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #194 of 301 Healthcare | #193 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AXSM fair value analysis · PSNL fair value analysis